<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Young, Jr, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The syndrome of apparent mineralocorticoid excess (AME), a genetic disorder, and chronic ingestion of licorice (the root of glycyrrhiza glabra), licorice-like compounds (such as carbenoxolone), or triazole antifungals (<a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> and <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>) can result in findings similar to those in primary aldosteronism: hypertension, hypokalemia, metabolic alkalosis, and low plasma renin activity. However, plasma aldosterone levels are low in these disorders, rather than elevated, as in primary aldosteronism. (See  <a class="medical medical_review" href="/z/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism"</a> and  <a class="medical medical_review" href="/z/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism"</a>.)</p><p>The pathogenesis of these disorders has been elucidated. Summarized briefly, renal mineralocorticoid receptors bind aldosterone and cortisol with similar affinity. Although the plasma concentration of cortisol is approximately 100-fold higher than aldosterone, activation of mineralocorticoid receptors by cortisol is normally limited due to its conversion to inactive cortisone at the sites of aldosterone action by the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (11-beta-HSD2) [<a href="#rid1">1</a>]. This conversion is impaired in AME because of a pathogenic variant in the 11-beta-HSD2 gene and by licorice ingestion or treatment with triazole antifungals because these agents inhibit the enzyme [<a href="#rid2">2</a>]. (See <a class="local">'Pathogenesis'</a> below.)</p><p>By somewhat different mechanisms, hypersecretion of cortisol can also induce an excess mineralocorticoid state in patients with ectopic ACTH syndrome [<a href="#rid3">3</a>]. (See <a class="local">'Ectopic ACTH syndrome'</a> below.)</p><p>Other hypermineralocorticoid states are presented separately. (See  <a class="medical medical_review" href="/z/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SYNDROME OF APPARENT MINERALOCORTICOID EXCESS</span></p><p class="headingAnchor" id="H64559743"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>The syndrome of apparent mineralocorticoid excess (AME) is a rare form of severe juvenile hypertension that is usually transmitted as an autosomal recessive trait [<a href="#rid4">4-6</a>]. AME is characterized by low birth weight, failure to thrive, onset of severe hypertension in early childhood with extensive target organ damage, hypercalciuria and nephrocalcinosis from an unknown mechanism, and kidney failure [<a href="#rid7">7</a>]. These manifestations are accompanied by all of the findings of primary aldosteronism (hypertension, hypokalemia, metabolic alkalosis, and low plasma renin activity) except for the low plasma aldosterone concentration. Affected patients may also have polyuria due to arginine vasopressin resistance (previously called nephrogenic diabetes insipidus) that is presumably induced by the chronic hypokalemia [<a href="#rid4">4,8</a>]. (See  <a class="medical medical_review" href="/z/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism"</a> and  <a class="medical medical_review" href="/z/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p>A late-onset syndrome has been reported in adults with compound heterozygous pathogenic variants who have a milder phenotype [<a href="#rid9">9</a>]. The heterozygous mothers of two probands had a phenotype indistinguishable from primary hypertension (formerly called "essential" hypertension). Another patient with a different pathogenic variant also had less severe disease with low-renin hypertension in the absence of hypokalemia [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The syndrome of AME is due to deficiency in the 11-beta-hydroxysteroid dehydrogenase enzyme type 2 isoform (11-beta-HSD2), which is the kidney isoform of 11-beta-HSD [<a href="#rid11">11</a>].</p><p>11-beta-HSD2 normally converts cortisol to cortisone, a steroid that does not bind to the mineralocorticoid receptor [<a href="#rid11">11</a>]. This effect is physiologically important, because cortisol binds as avidly as aldosterone to the mineralocorticoid receptor, and the plasma cortisol concentration is approximately 100-fold higher than the plasma aldosterone concentration.</p><p>Thus, cortisol would be the primary mineralocorticoid if it were not converted by 11-beta-HSD2 to cortisone at the aldosterone-sensitive sites. The persistence of cortisol resulting from deficiency in 11-beta-HSD2 leads to an often marked elevation in net mineralocorticoid activity.</p><p class="headingAnchor" id="H4"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>The defect in the syndrome of AME is due to pathogenic variants in the 11-beta-HSD2 gene, located on chromosome 16, which encodes the kidney isoform of 11-beta-HSD [<a href="#rid12">12</a>]. A number of different pathogenic variants have been found, and a defect has been noted in all patients tested [<a href="#rid6">6,7,9,13,14</a>].</p><p>Some of these pathogenic variants result only in partial inhibition of the 11-beta-HSD2 gene. There is a rough correlation between the severity of the enzymatic defect induced by these pathogenic variants and the clinical findings, including the ratio of cortisol to cortisone metabolites and the clinical course [<a href="#rid4">4,6,10</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The predominant clinical features of the syndrome of AME are hypertension and, in infants, low birth weight, failure to thrive, and muscle weakness due to hypokalemia. Patients with full expression of the syndrome may also have hypercalciuria, nephrocalcinosis, and kidney function impairment.</p><p>The biochemical abnormalities suggesting the diagnosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypokalemia</p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic alkalosis</p><p class="bulletIndent1"><span class="glyph">●</span>Low plasma renin activity</p><p class="bulletIndent1"><span class="glyph">●</span>Low plasma aldosterone levels</p><p></p><p>The urinary free cortisol to urinary free cortisone ratio as measured on a 24-hour urine collection is a sensitive diagnostic test [<a href="#rid15">15,16</a>]. If 11-beta-HSD is functioning normally, urinary free cortisone levels exceed urinary cortisol levels, and the ratio of cortisol to cortisone is approximately 0.3 to 0.5 [<a href="#rid17">17</a>].</p><p>In most patients with a defective enzyme, the urinary free cortisone levels are very low or undetectable, so the ratio of cortisol to cortisone is very high [<a href="#rid7">7</a>]. In classically affected patients with the syndrome of AME, the ratio was 5 in children and 18 in adults [<a href="#rid15">15,17</a>].</p><p>Genetic testing to confirm the diagnosis of the syndrome of AME is commercially available. A list of clinically approved molecular genetic diagnostic laboratories is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=2346" target="_blank">www.ncbi.nlm.nih.gov/gtr/</a>.</p><p class="headingAnchor" id="H6"><span class="h3">Differential diagnosis</span><span class="headingEndMark"> — </span>The presenting symptoms and signs of AME are similar to those of primary aldosteronism, but the plasma aldosterone concentration is low. (See  <a class="medical medical_review" href="/z/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism"</a>.)</p><p>Licorice ingestion, treatment with triazole antifungals (<a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> and <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>), and ectopic ACTH syndrome, which are described below, can present with biochemical findings that are similar to those of the syndrome of AME. However, measurement of urinary free cortisol and cortisone levels permits differentiation of these disorders [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>With licorice ingestion, urinary free cortisone is only modestly decreased, and the ratio of cortisol to cortisone is therefore only modestly elevated (eg, &gt;1; normal 0.3 to 0.5).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with the triazole antifungals <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> and <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> can mimic AME [<a href="#rid18">18,19</a>]. Both of these triazole antifungals potently inhibit CYP11B1 and 11-beta-HSD2 [<a href="#rid18">18</a>]. The development of clinical features in patients treated with posaconazole is dose dependent, occurring primarily in those with drug levels &gt;3 mcg/mL. Substitution with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a>, or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> leads to resolution of symptoms and signs [<a href="#rid18">18,19</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ectopic ACTH production may result in a similarly elevated urinary free cortisol to cortisone ratio, but urinary cortisol and cortisone levels are markedly increased in contrast to the very low levels of urinary free cortisone excretion in the syndrome of AME. (See  <a class="medical medical_review" href="/z/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a>.)</p><p></p><p>AME must also be distinguished from other rare causes of mineralocorticoid excess in which aldosterone levels are reduced, including Liddle syndrome (due to a gain-of-function mutation in the collecting tubule sodium channel), deoxycorticosterone-secreting tumors, deficiency in the 5-reductase enzyme (leading to defective conversion and thus persistently high levels of cortisol), and two forms of congenital adrenal hyperplasia [<a href="#rid20">20</a>]. Urinary cortisol metabolites are normal in the first two disorders. (See  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on '11-beta-hydroxylase deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'CYP17A1 deficiencies'</a> and  <a class="medical medical_review" href="/z/d/html/138.html" rel="external">"Diagnosis of primary aldosteronism", section on 'Other causes of hypertension and hypokalemia'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Therapy</span><span class="headingEndMark"> — </span>Therapy of the syndrome of AME has been directed at reducing endogenous cortisol production or blocking the mineralocorticoid receptor [<a href="#rid21">21</a>].</p><p><a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> has been given in doses of 1.5 to 2 mg/day to suppress ACTH and reduce endogenous cortisol production without appreciably activating the mineralocorticoid receptor. However, dexamethasone does not correct the hypokalemia and hypertension in all patients, and long-term therapy has adverse effects [<a href="#rid1">1</a>]. Thus, we use dexamethasone only if mineralocorticoid blockade is not effective or not tolerated.</p><p>We prefer therapy based upon blockade of mineralocorticoid effects, which can be achieved by decreasing sodium channel activity with <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> or <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a> or by direct mineralocorticoid receptor blockade with <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> or <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a> [<a href="#rid21">21,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/2338.html" rel="external">"Mechanism of action of diuretics"</a>.)</p><p>Direct comparison of these agents is unavailable, but it has been suggested that high doses of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> (with a higher likelihood of side effects) are required to block the mineralocorticoid effects of cortisol [<a href="#rid1">1</a>]. It seems reasonable to initiate therapy with drugs with fewer side effects, particularly in men (eg, <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> or <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a>). The end point of therapy has not been clearly defined, but normalization of the plasma potassium concentration and plasma renin activity (eg, &gt;1 ng/mL/hour) are reasonable treatment targets. Similar goals are recommended in patients with primary aldosteronism who are treated medically. (See  <a class="medical medical_review" href="/z/d/html/141.html" rel="external">"Treatment of primary aldosteronism"</a>.)</p><p>Potassium supplements may be required initially to treat hypokalemia but should not be needed after the attainment of mineralocorticoid antagonism. (See  <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults"</a>.)</p><p>A thiazide is indicated if hypercalciuria or nephrocalcinosis is present [<a href="#rid1">1,4</a>]. (See  <a class="medical medical_review" href="/z/d/html/7373.html" rel="external">"Kidney stones in adults: Prevention of recurrent kidney stones", section on 'High urine calcium'</a>.)</p><p>Cure has been reported in two patients after transplantation of a kidney with normal 11-beta-HSD2 activity [<a href="#rid23">23,24</a>].</p><p class="headingAnchor" id="H8"><span class="h1">LICORICE INGESTION</span><span class="headingEndMark"> — </span>Chronic ingestion of licorice or licorice-like compounds (such as carbenoxolone) induces a syndrome with findings similar to those with the syndrome of apparent mineralocorticoid excess (AME): hypertension, hypokalemia, metabolic alkalosis, low plasma renin activity and low plasma aldosterone levels [<a href="#rid25">25</a>].</p><p>Relatively small amounts of confectionery licorice, as little as 50 g daily for two weeks, produce a rise in blood pressure in normal people [<a href="#rid26">26</a>]. Licorice contains a steroid, glycyrrhetinic acid, that inhibits (both competitively and by reducing gene expression) 11-beta-HSD2, the same enzyme that is deficient in AME [<a href="#rid27">27</a>]. As in AME, normal levels of cortisol can markedly increase net mineralocorticoid activity in patients chronically ingesting licorice [<a href="#rid27">27</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p>The diagnosis is typically based upon the biochemical abnormalities and an elicited history of licorice ingestion [<a href="#rid28">28</a>]. The source of the ingested licorice may not be obvious; it is present, for example, in some forms of flavored chewing gum, chewing tobacco, licorice-infused marijuana, and tea [<a href="#rid29">29-31</a>]. As noted above, urinary free cortisone and cortisol levels may help make the diagnosis, but such testing is not necessary if a history of licorice ingestion has been obtained. (See <a class="local">'Differential diagnosis'</a> above.)</p><p>Cessation of licorice ingestion (or other source of glycyrrhetinic acid) is usually the only treatment necessary. Potassium supplements or a potassium-sparing diuretic may be initially required to treat hypokalemia but should not be needed once the effect of licorice has worn off (typically less than one week).</p><p class="headingAnchor" id="H80039069"><span class="h1">TREATMENT WITH TRIAZOLE ANTIFUNGALS</span><span class="headingEndMark"> — </span>Treatment with the triazole antifungals <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> and <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> mimics AME [<a href="#rid18">18,19</a>]. Both of these triazole antifungals potently inhibit CYP11B1 and 11-beta-HSD2 [<a href="#rid18">18</a>]. </p><p>A systematic review of 18 studies documented 39 cases in which findings suggestive of AME developed following treatment with <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> [<a href="#rid19">19</a>]. The median duration of treatment before diagnosis was 11.5 weeks and was dose dependent, occurring primarily in those with drug levels &gt;3 mcg/mL. Substitution with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a>, or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> led to resolution of symptoms and signs [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H9"><span class="h1">ECTOPIC ACTH SYNDROME</span><span class="headingEndMark"> — </span>Cortisol can contribute to the excess mineralocorticoid effect in Cushing syndrome due to ectopic ACTH release (most commonly arising from small cell carcinoma of the lung) [<a href="#rid32">32</a>]. This can occur by the following mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>Cortisol secretion may be so high that it exceeds the metabolic capacity of 11-beta-HSD2 [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very high circulating levels of ACTH may inhibit 11-beta-HSD2 [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypersecretion of nonaldosterone mineralocorticoids such as deoxycorticosterone [<a href="#rid34">34</a>]. </p><p></p><p>The diagnosis of the ectopic ACTH syndrome is suggested by hypokalemia, the demonstration of markedly increased 24-hour urinary free cortisol excretion, and elevated serum ACTH. A cushingoid appearance may be present but these features can be minimal in patients with malignancies. (See  <a class="medical medical_review" href="/z/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H1216781162"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">"Society guideline links: Fluid and electrolyte disorders in adults"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apparent mineralocorticoid excess syndrome</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pathogenesis – Congenital (syndrome of apparent mineralocorticoid excess [AME]) and acquired (chronic licorice ingestion or treatment with triazole antifungals) deficiencies of the 11-beta-hydroxysteroid dehydrogenase enzyme type 2 isoform (11-beta-HSD2) lead to failure of conversion of cortisol to cortisone at aldosterone binding sites, such as the kidney cortical collecting tubules. Cortisol binds avidly to the mineralocorticoid receptor in the kidneys, and without the normal conversion to cortisone, usual levels of cortisol production induce a mineralocorticoid excess state. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent2">Cortisol can also contribute to the mineralocorticoid excess in Cushing syndrome due to ectopic ACTH release via a variety of mechanisms. (See <a class="local">'Ectopic ACTH syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical manifestations – Excess mineralocorticoid activity leads directly to sodium retention, hypertension, hypokalemia, metabolic alkalosis, low plasma renin activity, and, in contrast to primary aldosteronism, low plasma aldosterone. In addition, the syndrome of AME, a rare autosomal recessive disorder, is characterized by low birth weight, failure to thrive, muscle weakness, and severe hypertension in early childhood, often with hypercalciuria, nephrocalcinosis, polyuria due to hypokalemia-induced arginine vasopressin resistance (previously called nephrogenic diabetes insipidus), and kidney failure. (See <a class="local">'Syndrome of apparent mineralocorticoid excess'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of these disorders is largely based upon the history, clinical features, and the associated biochemical abnormalities, including the low plasma renin activity and aldosterone level. If a history of chronic licorice ingestion or treatment with triazole antifungals is not elicited, we suggest obtaining a 24-hour urine collection to measure the urinary free cortisol and free cortisone, and determining the ratio (see <a class="local">'Differential diagnosis'</a> above). The diagnosis of ectopic ACTH is characterized by markedly increased 24-hour urinary free cortisol excretion and elevated serum ACTH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – With licorice ingestion, therapy simply involves stopping the ingestion of licorice (or other source of glycyrrhetinic acid). With triazole antifungal treatment, substitution with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a>, or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> leads to resolution of symptoms and signs. The treatment of Cushing syndrome is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent1">The optimal therapy of the syndrome of AME is unknown. We suggest the following approach (see <a class="local">'Therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Potassium repletion, if required for hypokalemia. This can be discontinued once therapy with mineralocorticoid antagonism is instituted. (See  <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest antagonism of mineralocorticoid effects with <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> or <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have hypercalciuria or nephrocalcinosis, we suggest therapy with a thiazide diuretic (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> to suppress ACTH and reduce endogenous cortisol production only if mineralocorticoid antagonism is not effective or not tolerated (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent1">The end point of therapy has not been clearly defined, but normalization of the plasma potassium concentration and normalization of plasma renin activity (eg, &gt;1 ng/mL/hour) are reasonable treatment targets. Similar goals are recommended in patients with primary aldosteronism who are treated medically. (See  <a class="medical medical_review" href="/z/d/html/141.html" rel="external">"Treatment of primary aldosteronism"</a>.)</p><p></p><p class="headingAnchor" id="H749310740"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledges Norman M Kaplan, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003; 88:2384.</a></li><li><a class="nounderline abstract_t">Stewart PM. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur J Endocrinol 2003; 149:163.</a></li><li><a class="nounderline abstract_t">Ulick S, Wang JZ, Blumenfeld JD, Pickering TG. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1992; 74:963.</a></li><li><a class="nounderline abstract_t">Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1998; 83:2244.</a></li><li><a class="nounderline abstract_t">Funder JW. Apparent mineralocorticoid excess. J Steroid Biochem Mol Biol 2017; 165:151.</a></li><li><a class="nounderline abstract_t">Adamidis A, Cantas-Orsdemir S, Tsirka A, et al. Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature. Pediatr Endocrinol Rev 2019; 16:335.</a></li><li><a class="nounderline abstract_t">Morineau G, Sulmont V, Salomon R, et al. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J Am Soc Nephrol 2006; 17:3176.</a></li><li><a class="nounderline abstract_t">Bockenhauer D, van't Hoff W, Dattani M, et al. Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases. Nephron Physiol 2010; 116:p23.</a></li><li><a class="nounderline abstract_t">Lavery GG, Ronconi V, Draper N, et al. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 2003; 42:123.</a></li><li><a class="nounderline abstract_t">Wilson RC, Dave-Sharma S, Wei JQ, et al. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci U S A 1998; 95:10200.</a></li><li><a class="nounderline abstract_t">Funder JW. 11 beta-Hydroxysteroid dehydrogenase: new answers, new questions. Eur J Endocrinol 1996; 134:267.</a></li><li><a class="nounderline abstract_t">Mune T, Rogerson FM, Nikkilä H, et al. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 1995; 10:394.</a></li><li><a class="nounderline abstract_t">Carvajal CA, Gonzalez AA, Romero DG, et al. Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 2003; 88:2501.</a></li><li><a class="nounderline abstract_t">Yau M, Azkawi HS, Haider S, et al. A novel mutation in HSD11B2 causes apparent mineralocorticoid excess in an Omani kindred. Ann N Y Acad Sci 2016; 1376:65.</a></li><li><a class="nounderline abstract_t">Palermo M, Delitala G, Mantero F, et al. Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone. J Endocrinol Invest 2001; 24:17.</a></li><li><a class="nounderline abstract_t">Antonelli G, Artusi C, Marinova M, et al. Cortisol and cortisone ratio in urine: LC-MS/MS method validation and preliminary clinical application. Clin Chem Lab Med 2014; 52:213.</a></li><li><a class="nounderline abstract_t">Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 1996; 45:605.</a></li><li><a class="nounderline abstract_t">Beck KR, Odermatt A. Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess. Mol Cell Endocrinol 2021; 524:111168.</a></li><li><a class="nounderline abstract_t">Ji HH, Tang XW, Zhang N, et al. Antifungal Therapy with Azoles Induced the Syndrome of Acquired Apparent Mineralocorticoid Excess: a Literature and Database Analysis. Antimicrob Agents Chemother 2022; 66:e0166821.</a></li><li><a class="nounderline abstract_t">Ulick S, Tedde R, Wang JZ. Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab 1992; 74:593.</a></li><li><a class="nounderline abstract_t">Razzaghy-Azar M, Yau M, Khattab A, New MI. Apparent mineralocorticoid excess and the long term treatment of genetic hypertension. J Steroid Biochem Mol Biol 2017; 165:145.</a></li><li><a class="nounderline abstract_t">Speiser PW, Riddick LM, Martin K, New MI. Investigation of the mechanism of hypertension in apparent mineralocorticoid excess. Metabolism 1993; 42:843.</a></li><li><a class="nounderline abstract_t">Palermo M, Cossu M, Shackleton CH. Cure of apparent mineralocorticoid excess by kidney transplantation. N Engl J Med 1998; 339:1787.</a></li><li><a class="nounderline abstract_t">Khattab AM, Shackleton CH, Hughes BA, et al. Remission of hypertension and electrolyte abnormalities following renal transplantation in a patient with apparent mineralocorticoid excess well documented throughout childhood. J Pediatr Endocrinol Metab 2014; 27:17.</a></li><li><a class="nounderline abstract_t">Farese RV Jr, Biglieri EG, Shackleton CH, et al. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325:1223.</a></li><li><a class="nounderline abstract_t">Sigurjónsdóttir HA, Franzson L, Manhem K, et al. Liquorice-induced rise in blood pressure: a linear dose-response relationship. J Hum Hypertens 2001; 15:549.</a></li><li><a class="nounderline abstract_t">Whorwood CB, Sheppard MC, Stewart PM. Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology 1993; 132:2287.</a></li><li><a class="nounderline abstract_t">McHugh J, Nagabathula R, Kyithar MP. A life-threatening case of pseudo-aldosteronism secondary to excessive liquorice ingestion. BMC Endocr Disord 2021; 21:158.</a></li><li><a class="nounderline abstract_t">de Klerk GJ, Nieuwenhuis MG, Beutler JJ. Hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum. BMJ 1997; 314:731.</a></li><li><a class="nounderline abstract_t">Gallacher SD, Tsokolas G, Dimitropoulos I. Liquorice-induced apparent mineralocorticoid excess presenting in the emergency department. Clin Med (Lond) 2017; 17:43.</a></li><li><a class="nounderline abstract_t">Latif A, Naqi M, McAnally JF. A Case of Liquorice-Infused Marijuana Causing Syndrome of Apparent Mineralocorticoid Excess. Eur J Case Rep Intern Med 2023; 10:003991.</a></li><li><a class="nounderline abstract_t">Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2002; 970:134.</a></li><li><a class="nounderline abstract_t">Walker BR, Campbell JC, Fraser R, et al. Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1992; 37:483.</a></li><li><a class="nounderline abstract_t">CHRISTY NP, LARAGH JH. Pathogenesis of hypokalemic alkalosis in Cushing's syndrome. N Engl J Med 1961; 265:1083.</a></li></ol></div><div id="topicVersionRevision">Topic 2346 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788832" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypertension and the cortisol-cortisone shuttle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12943516" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1569172" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661590" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26956190" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Apparent mineralocorticoid excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30888125" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035606" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Apparent mineralocorticoid excess: report of six new cases and extensive personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733335" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860834" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9707624" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A genetic defect resulting in mild low-renin hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8616521" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 11 beta-Hydroxysteroid dehydrogenase: new answers, new questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7670488" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788846" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27526338" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A novel mutation in HSD11B2 causes apparent mineralocorticoid excess in an Omani kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11227727" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24391193" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cortisol and cortisone ratio in urine: LC-MS/MS method validation and preliminary clinical application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8977758" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33484741" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34662186" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antifungal Therapy with Azoles Induced the Syndrome of Acquired Apparent Mineralocorticoid Excess: a Literature and Database Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740492" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26892095" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8393954" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Investigation of the mechanism of hypertension in apparent mineralocorticoid excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9867558" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cure of apparent mineralocorticoid excess by kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945123" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Remission of hypertension and electrolyte abnormalities following renal transplantation in a patient with apparent mineralocorticoid excess well documented throughout childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1922210" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Licorice-induced hypermineralocorticoidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11494093" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Liquorice-induced rise in blood pressure: a linear dose-response relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504732" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34362360" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A life-threatening case of pseudo-aldosteronism secondary to excessive liquorice ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9116553" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28148579" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Liquorice-induced apparent mineralocorticoid excess presenting in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37680778" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A Case of Liquorice-Infused Marijuana Causing Syndrome of Apparent Mineralocorticoid Excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12381548" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1337504" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13879332" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pathogenesis of hypokalemic alkalosis in Cushing's syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
